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 INTRODUCTION 
Cirrhosis represents the final common histologic pathway for a 
wide variety of chronic liver diseases. The term cirrhosis was first 
introduced by Laennec in 1826. 
  Cirrhosis is defined histologically as a diffuse hepatic process 
characterized by diffuse alteration in the hepatic architecture 
characterized by on-going fibrosis and regenerative nodules. The 
progression of liver injury to cirrhosis may occur over weeks to years. 
The development of hepatic fibrosis reflects an alteration in the 
normally balanced processes of extracellular matrix production and 
degradation. Extracellular matrix, the normal scaffolding for hepatocytes, 
is composed of collagens (especially types I, III, and V), glycoproteins, 
and proteoglycans. Stellate cells, located in the peri sinusoidal space, are 
essential for the production of extracellular matrix. Stellate cells, which 
were once known as Ito cells, lipocytes, or perisinusoidal cells, may 
become activated into collagen-forming cells by a variety of paracrine 
factors. Such factors may be released by hepatocytes, Kupffer cells, and 
sinusoidal endothelium following liver injury. 
Increased collagen deposition in the space of Disse (the space 
between hepatocytes and sinusoids) and the diminution of the size of 
endothelial fenestrae lead to the capillarization of sinusoids. Activated 
 stellate cells also have contractile properties. Both capillarization and 
constriction of sinusoids by stellate cells contribute to the development of 
portal hypertension.  
The portal vein carries approximately 1500 mL/min of blood from 
the small and large bowel, the spleen, and the stomach to the liver. 
Obstruction of portal venous flow, as in cirrhosis, results in a rise in 
portal venous pressure. The response to increased venous pressure is the 
development of a collateral circulation diverting the obstructed blood 
flow to the systemic veins. These porto systemic collaterals form by the 
opening and dilatation of pre-existing vascular channels connecting the 
portal venous system and the superior and inferior vena cava. 
The prevalence of oesophageal varices in patients with liver 
cirrhosis may range from 60% to 80%, and the reported mortality from 
variceal bleeding ranges from 17% to 57%. Cirrhotic patients with Portal 
Hypertension who develop oesophageal varices are at a very high risk of 
variceal bleeding and Variceal rupture is a common cause of death in 
cirrhosis.
(3,38,39)
 
Normal pressure in the portal vein is 5-10 mm Hg because the 
vascular resistance in the hepatic sinusoids is low. An elevated portal 
venous pressure (>10 mm Hg) distends the veins proximal to the site of 
the block and increases capillary pressure in organs drained by the 
 obstructed veins. This will lead to the development of esophagial and 
fundal varices. One third of the gastrointestinal bleedings reveal pre-
existent cirrhosis. In patients with cirrhosis the incidence of oesophageal 
varices increases by nearly 5% per year, and the rate of progression from 
small to large varices is approximately 5 to 10 % per year. The risk of 
variceal rupture is greatest in the 2 years following diagnosis. 
In the 2 years following the first detection of esophageal varices , 
risk of variceal bleeding ranges between 20% to 30% and results in a 
mortality of 25% to 50% within a week of the first bleeding episode. 
Therefore, portal hypertensive bleeding prevention remains at the 
forefront of the long-term management of cirrhotic patients. As there is 
clear evidence that primary prevention of variceal rupture is cost effective 
in reducing death rate, screening for oesophageal varices (EV) is 
recommended. 
Prophylactic treatment in patients with non-selective Beta blockers 
in varices that has never bled appears to decrease the incidence of 
bleeding by 40 to 50 % and prolong survival. So endoscopic screening for 
varices in patients with cirrhosis is desirable, some have suggested this 
should be repeated every other year.
 (8,9,40,41)
 
The American Association for the Study of Liver Disease single 
topic Symposium 
(1)
 1996 stated that cirrhotic patients should be screened 
 for the presence of esophageal varices when portal hypertension is 
diagnosed. Recently, the Baveno III Consensus Conference 
(2)
 on portal 
hypertension recommended that all cirrhotic patients should be screened 
for the presence of esophageal varices when liver cirrhosis is diagnosed. 
Other authors 
(3)
 have suggested repeating endoscopy at 2–3 year 
intervals in patients without varices and at 1–2 year intervals in patients 
with small varices and every other year in patients with decompensated 
liver disease so as to evaluate the development or progression of this 
feature. 
Endoscopic screening may take place under two circumstances: at 
the initial diagnosis of cirrhosis, since esophageal varices are an 
independent predictive factor and an early complication of cirrhosis, and 
during the follow-up of patients with cirrhosis without esophageal varices 
at risk of bleeding at first examination with or without 
decompensation.
(34)
 
It has been estimated that it is only the large esophageal varices 
(LEV), which are associated with a substantially increased risk of 
variceal bleed. The reported incidence of LEV ranges from 9% to 49% 
(4)
. 
In a recent review, Boyer,
(5)
 using a prevalence of LEV of 20%, estimated 
that a 100 screening endoscopic examinations need to be performed to 
prevent 1 to 2 cases of variceal bleeding. It is noteworthy however that 
 variceal hemorrhage is not confined to patients with large esophageal 
varices although they are more likely to bleed from ruptured varices than 
patients with small esophageal varices . 
Cirrhotic patients frequently undergo screening endoscopy for the 
presence of esophageal varices (EV). In the future, this social and 
medical burden will increase due to the greater number of patients with 
chronic liver disease and their improved survival. 
Therefore, the identification of the clinical features that can 
accurately predict LEV and help identify patients at the greatest risk of 
bleeding is quite attractive. This could thus make it possible to identify 
the population with a high probability of LEV that requires confirmation 
by endoscopy, since the regular use of endoscopy is limited due to cost 
and discomfort, resulting in poor compliance. 
The usual clinical practice is to screen all patients with established 
cirrhosis at the time of diagnosis by upper endoscopy for the presence of 
varices. Patients with large varices should be treated with non-selective 
beta blockers to reduce the incidence of first variceal bleeding. However, 
fewer than 50% of cirrhotic patients have varices at screening endoscopy 
and most have small sized varices, with a low risk of bleeding. 
In order to reduce the increasing burden that endoscopy units will 
have to bear, some studies have attempted to identify characteristics that 
 noninvasively predict the presence of any oesophageal varices or of large 
oesophageal varices . These studies have shown that biochemical, 
clinical, and ultrasonographic parameters alone or together have good 
predictive power for non-invasively assessing the presence of esophageal 
varices . Overall, the most common result of these studies was that 
parameters directly or indirectly linked to portal hypertension, such as 
splenomegaly and decreased platelet count, were predictors of the 
presence of esophageal varices. 
In a study by Thomopoulos et al (2003)
 (32)
 seventeen variables 
considered relevant to the presence of esophageal varices were tested and 
they came to the conclusion that Thrombocytopenia, splenomegaly and 
ascites are independent predictors of large esophageal varices in cirrhotic 
patients.The authors suggest that endoscopy could be avoided safely in 
cirrhotic patients with none of these predictive factors, as large varices 
are absent in this group of patients. However, in patients with chronic 
liver disease the presence of decreased platelet count may depend on 
several factors other than portal hypertension, such as shortened platelet 
mean lifetime, decreased thrombopoietin production, or myelotoxic 
effects of alcohol or hepatitis viruses. On the other hand, the presence of 
splenomegaly in cirrhotic patients is likely the result of vascular 
disturbances that are mainly related to portal hypertension. With this in 
 mind, according to Gianni et al(2003)
(3)
, their study used the platelet 
count/spleen diameter ratio as a parameter linking thrombocytopenia to 
spleen size in order to introduce a variable that takes into consideration 
the decrease in platelet count, which most likely depends on 
hypersplenism.
 (30,31)
 
Since both platelet count and splenomegaly are influenced by so 
many factors other than portal pressure, it is worthwhile if we could move 
on, in the search of better non-invasive predictors of esophagial varices 
that are more sensitive and less cumbersome both for the patient and the 
treating physician. This will help us in identifying the suitable candidates 
for the initiation of prophylactic beta blockade so that a catastrophic 
variceal bleed can be predicted and prevented.
 (37)
 
 
 
 
 
 
 
 
 
 
  
 
 
 
AIMS AND OBJECTIVES 
 
1. To validate the usefulness of Doppler study of the Hepatic veins in 
predicting esophageal varices in cirrhotic patients. 
2. To compare the sensitivity and positive predictive value of Doppler 
study of hepatic veins to other suggested indices like platelet 
count/spleen size in non-invasively predicting the possibility of 
esophageal varices. 
3. To assess the correlation between hepatic venous wave forms and 
Child Pugh score in the grading of severity of Cirrhosis. 
 
 
 
 
 
 
 REVIEW OF LITERATURE 
Cirrhosis is a pathologically defined entity that is associated with a 
spectrum of clinical manifestations.
(6)
 
Definition 
A chronic disease of the liver characterized by the replacement of 
normal tissue with fibrous tissue and the loss of functional liver cells. 
It is characterized by three cardinal features. 
1. Loss of normal hepatic architecture. 
2. Fibrosis. 
3. Regenerative nodules. 
Evolution of cirrhosis
(7)
 
The cardinal pathological features reflect irreversible chronic 
injury of the hepatic parenchyma and include extensive fibrosis in 
association with formation of regenerative nodules. These features result 
from hepatocyte necrosis, collapse of supporting reticulin network with 
subsequent connective tissue deposition, distortion of vascular bed, and 
nodular regeneration of remaining liver parenchyma. The pathologic 
process should be viewed as a final common pathway of many types of 
chronic liver injury. Clinical features of cirrhosis derive from the 
morphological alterations and often reflect the severity of hepatic damage 
rather than the aetiology of the underlying liver disease. Loss of 
 functioning hepatocellular mass may lead to jaundice, oedema, 
coagulopathy, and a variety of metabolic abnormalities; fibrosis and 
distorted vasculature lead to portal hypertension and its sequel, including 
gastro oesophageal varices and splenomegaly. Ascites and hepatic 
encephalopathy result from both hepatocellular insufficiency and portal 
hypertension. 
Classification of cirrhosis.
 (8)
 
The pathological patterns of cirrhosis represents a spectrum. At one 
end is the Micronodular cirrhosis and at the other end is the macronodular 
cirrhosis. Between these two extreme types are so many cases that show 
features of both. 
1.Micronodular cirrhosis. 
 Nodules < 3mm in diameter. The nodules show no landmarks of 
lobular architecture, in the form of bile ducts or central veins. 
Alcoholic cirrhosis is the prototype of micronodlar cirrhosis. 
2. Macronodular cirrhosis. 
 Nodules are >3mm in diameter and the intervening septa in 
between the necrotic nodules do retain landmarks of hepatic architecture. 
Cirrhosis secondary to Chronic viral hepatitis is the prototype of 
Macronodular cirrhosis. It is also seen in malnutrition, old age and 
anemia.  
 3. Mixed pattern 
Micronodular pattern can be converted into macronodular pattern 
by continued regeneration and expansion of the nodules, especially seen 
when the patient abstains from alcohol for a long time. 
Aetiology 
1.  Alcohol. 
2.  Viral hepatitis types B ± delta; C. 
3.  Metabolic, e.g. hemochromatosis, Wilson's disease, α1 antitrypsin 
deficiency, type IV glycogenosis, galactosaemia, congenital 
tyrosinosis and non-alcoholic steatohepatitis. 
4.  Prolonged cholestasis, intra-and extra-hepatic. 
5.  Hepatic venous outflow obstruction, e.g. venoocclusive disease, 
Budd-Chiari syndrome, constrictive pericarditis. 
6.  Disturbed immunity (autoimmune hepatitis). 
7.  Toxins and therapeutic agents, e.g. methotrexate, amiodarone. 
8.  Indian childhood cirrhosis. 
9.  Cryptogenic cirrhosis. 
Aetiology: 
1.  Alcohol. 
2.  Viral hepatitis types B ± delta; C. 
3.  Metabolic, e.g. haemochromatosis, Wilson's disease, α1 antitrypsin 
deficiency, type IV glycogenosis, galactosaemia, congenital 
tyrosinosis and non-alcoholic steatohepatitis. 
 4.  Prolonged cholestasis, intra-and extra-hepatic. 
5.  Hepatic venous outflow obstruction, e.g. venoocclusive disease, 
Budd-Chiari syndrome, constrictive pericarditis. 
6.  Disturbed immunity (autoimmune hepatitis). 
7.  Toxins and therapeutic agents, e.g. methotrexate, amiodarone. 
8.  Indian childhood cirrhosis. 
9.  Cryptogenic cirrhosis. 
Diagnosis of cirrhosis
(6,7,8)
 
A) Clinical history  
Fatigue and weight loss, loss of libido, anorexia and flatulent 
dyspepsia, abdominal pain, Jaundice, swelling of legs or abdomen, 
hemorrhage - nose, gums, skin, alimentary tract. 
Past history: jaundice, hepatitis, drugs ingested, blood transfusion. 
Social: alcohol consumption. 
B) Examination: 
Nutrition, fever, fetor hepaticus, jaundice, pigmentation, purpura, 
finger clubbing, white nails, vascular spiders, palmar erythema, 
gynaecomastia, testicular atrophy, distribution of body hair. 
Abdomen: ascites, abdominal wall veins, liver, spleen, oedema 
Neurological changes: mental functions, stupor, and tremor 
 
 C) Investigations : 
Haematology 
• Hemoglobin 
• Leukocyte count 
• Platelet count 
• Prothrombin time 
Serum biochemistry 
• Bilirubin 
• Transaminases Immunoglobulins 
• Alkaline phosphatase 
• γ - Glutamyl transpeptidase 
• Albumin and globulin 
If ascites present 
• Serum electrolytes. 
• Daily weight. 
• Urea and creatinine. 
• 24 hours urinary volume and sodium. 
• SAAG 
Serum immunological investigations 
• Hepatitis B Ag, Anti HCV. 
• Alpha-fetoprotein. 
• Smooth muscle, mitochondrial, nuclear antibodies. 
 Hepatic CT scan or ultrasound : 
Using ultrasound, cirrhosis is suggested by line surface nodularity 
and portal vein mean flow velocity. The caudate lobe is enlarged relative 
to the right lobe. Regeneration nodules may be shown as focal lesions.  
CT scan is cost-effective for the diagnosis of cirrhosis and its 
complications. Liver size can be assessed and the irregular nodular 
surface seen. After intravenous contrast, the portal vein and hepatic veins 
can be identified in the liver, and a collateral circulation with 
splenomegaly may give confirmation to the diagnosis of portal 
hypertension. Ascites can be seen. 
Liver biopsy : 
Biopsy diagnosis of cirrhosis may be difficult. Reticulin and 
collagen stains are essential for the demonstration of a rim of fibrosis 
around the nodule. 
EEG : EEG is indicated if neuropsychiatric changes are present and to 
detect early changes in pre-coma. 
Compensated cirrhosis 
(7,8)
 
The disease may be discovered at a routine examination or 
biochemical screen, or at operation undertaken for some other condition. 
Cirrhosis may be suspected if the patient has mild pyrexia, vascular 
spiders, palmar erythema, or unexplained epistaxis or oedema of the 
 ankles. Firm enlargement of the liver and splenomegaly are helpful 
diagnostic signs. 
Vague morning indigestion and flatulent dyspepsia may be early 
features in the alcoholic cirrhotic. Confirmation should be sought by 
biochemical tests, scanning and if necessary, by liver biopsy. 
Biochemical tests may be quite normal in this group. The most frequent 
changes are a slight increase in the serum transaminase or γ-GT level. 
Diagnosis is confirmed by needle liver biopsy. 
Decompensated cirrhosis 
The patient usually seeks medical advice because of ascites and or 
jaundice. General health fails with weakness, muscle wasting and weight 
loss. 
Continuous mild fever (37.5-38°C) is often due to gram-negative 
bacteraemia, to continuing hepatic cell necrosis or to liver cell carcinoma. 
A liver flap may be present. The deeper the jaundice, the greater the liver 
cell dysfunction. 
Pigmentation of the skin and clubbing of the fingers are 
occasionally seen. Purpura over the arms, shoulders and shins may be 
associated with a low platelet count. Spontaneous bruising and epistaxis 
reflect a prothrombin deficiency. The blood pressure is low. Sparse body 
hair, vascular spiders, palmar erythema, white nails and gonadal atrophy 
 are common. Ascites and oedema of the legs is frequently associated. The 
liver may be enlarged (early stages), with a regular edge, or contracted 
and impalpable (late stages). The spleen may be palpable. 
Child Pugh classification.
 (7,8,9)
 
 A B C 
S. Bilirubin <2.0 2-3 >3 
S. Albumin >3.5 2.8-3.5 <2.8 
Ascites None Slight or 
Controlled 
Moderate or 
Uncontrolled 
Encephalopathy None Minimal Coma 
ProthrombinTime (sec) 
Or INR 
0-4 
<1.7 
4-6 
1.7-2.3 
>6 
>2.3 
 
The total score classifies patients into grade A (5-7), B(7-9) Or 
C(>10). Poor prognosis is associated with a prolonged prothrombin time, 
marked ascites, gastrointestinal bleeding, advanced age, high daily 
alcohol consumption, high serum bilirubin and alkaline phosphatase, low 
albumin values, and poor nutrition. 
Patients with compensated cirrhosis become decompensated at the 
rate of 10% per year. Ascites is the usual first sign. Decompensated 
patients have around a 20% 5-year survival. 
 According to Madhotra et al (2002)
 (10)
 and Zaman et al (2001)
 (11)
 
the prevalence of esophageal varices in cirrhosis increases with severity 
of liver disease, as assessed by Child Pugh Classification. 
The following points are useful prognostically: 
•  Liver Size. A large liver carries a better prognosis than a small one 
because it is likely to contain more functioning cells. 
•  Hemorrhage from oesophageal varices. If liver function is good, 
hemorrhage may be tolerated; if poor, hepatic coma and death are 
probable. 
•  Persistent hypotension (systolic BP<100 mmHg) is ominous. 
•  Ascites worsens the prognosis. 
• If decompensation has followed hemorrhage, infection or 
alcoholism, the prognosis is better than if it is spontaneous, 
because the precipitating factor is correctable. 
•  Jaundice, especially if persistent, is a sign of terminal liver disease. 
•  Neurological complication. The significance of encephalopathy 
depends on the clinical circumstances. Developing in the course of 
progressive hepato-cellular failure, it carries a bad prognosis. 
•  Biochemical tests. If the serum albumin is less than 2.5g/dL the 
outlook is poor.  
 Hyponatraemia (serum sodium<120mmol/L), if unrelated to diuretic 
therapy, is grave.  
Serum transaminase and globulin levels gives no guide to prognosis. 
•  Alcoholic cirrhotics, if they abstain, respond better than those with 
'cryptogenic' cirrhosis. 
•  The response to therapy. If the patient has failed to improve within 
1 month of starting hospital treatment, the outlook is poor. 
•  Hepatic histological changes. Sections are useful in evaluating the 
extent of necrosis and of inflammatory infiltration. A fatty liver 
responds well to treatment.  
PORTAL HYPERTENSION 
ANATOMY OF THE PORTAL CIRCULATION. 
Portal vein is formed by union of superior mesenteric vein and 
splenic vein just posterior to the head of pancreas and it enters the liver at 
the porta hepatis and it divides into two main branches, one to each lobe. 
Portal blood flow in man is 1000- 1200mL/min. Portal pressure is about 
5-10 mm Hg. However, once the portal pressure rises to 12 mm Hg or 
greater, complications can arise, such as varices and ascites. 
  
PATHOPHYSIOLOGY. 
The initial factor in the pathophysiology of portal hypertension is 
the increase in vascular resistance to the portal blood flow. Poiseuille law, 
which can be applied to portal vascular resistance, states that R = 
8hL/pr4, where h is the viscosity of blood, L is the length of the blood 
vessel, and r is the radius of the blood vessel. Because portal vascular 
resistance is indirectly proportional to the fourth power of the vessel 
radius, small decreases in the vessel radius cause large increases in portal 
vascular resistance and, therefore, in portal blood pressure. 
 Liver disease is responsible for a decrease in portal vascular radius, 
producing a dramatic increase in portal vascular resistance. In cirrhosis, 
the increase occurs at the hepatic microcirculation (sinusoidal portal 
hypertension). Increased hepatic vascular resistance in cirrhosis is not 
only a mechanical consequence of the hepatic architectural disorder, but a 
dynamic component also exists due to the active contraction of 
myofibroblasts, activated stellate cells, and vascular smooth-muscle cells 
of the intrahepatic veins. 
The second factor that contributes to the pathogenesis of portal 
hypertension is the increase in blood flow in the portal veins, which is 
established through splanchnic arteriolar vasodilatation caused by an 
excessive release of endogenous vasodilators (eg, endothelial, neural, 
humoral). The increase in portal blood flow aggravates the increase in 
portal pressure and contributes to why portal hypertension exists despite 
the formation of an extensive network of portosystemic collaterals that 
may divert as much as 80% of portal blood flow.
 (11)
 
Formation of varices :  
The hypertensive portal vein is decompressed by diverting up to 
90% of the portal flow through portasystemic collaterals back to the heart 
resulting in enlargement of these vessels. These vessels are commonly 
located at the gastroesophageal junction where they lie subjacent to the 
 mucosa and present as gastric and esophageal varices. Varices form when 
the HVPG exceeds 10 mm Hg and usually do not bleed unless the hepatic 
venous pressure gradient (HVPG) exceeds 12 mm Hg.
 (12)
 
Mechanism of variceal haemorrhage:  
Increased portal pressure contributes to increased varix size and 
decreased varix wall thickness, thus leading to increased variceal wall 
tension. Rupture occurs when the wall tension exceeds the elastic limits 
of the variceal wall. Varices are most superficial at the gastroesophageal 
junction and have the thinnest wall in that region. Variceal hemorrhage 
invariably occurs in this region.
 (12)
  
Variceal haemorrhage is the most common complication associated 
with portal hypertension. Almost 90% of patients with cirrhosis develop 
varices, and approximately 30% of varices bleed. The first episode of 
variceal haemorrhage is estimated to carry a mortality rate of 30-50%. 
 
CLASSIFICATION AND CAUSES OF PORTAL HYPERTENSION(68)  
I)  Primary increased flow 
   1.  Arterioportal venous fistula. 
   2   Splenic capillary hemangiomatosis. 
 
 
 II ) Primary increased resistance 
1. Prehepatic:  
1.Thrombosis / cavernous transformation of the portal vein                   
2.Splenic vein thrombosis. 
2. Intrahepatic : 
1) Presinusoidal – Schistosomiasis,  
                              Sarcoidosis, 
Myeloproliferative diseases,                
Congenital hepatic fibrosis, 
Idiopathic portal hypertension, 
     Chronic arsenic hepatotoxicity, 
     Vinyl chloride hepatotoxicity, 
Early primary biliary cirrhosis,  
Early primary sclerosing cholangitis.  
2) Sinusoidal / mixed – cirrhosis, 
Methotrexate,  
Alcoholic hepatitis,  
Hypervitaminosis A, 
Incomplete septal fibrosis,  
Nodular regenerative hyperplasia.  
 
 3) Post sinusoidal – Veno-occlusive disease,  
Hepatic vein thrombosis(Budd-Chiari syndrome).  
3) Post hepatic – Inferior venacaval web, 
 Constrictive pericarditis, 
Tricuspid insufficiency,  
severe right heart failure. 
CLINICAL FEATURES OF PORTAL HYPERTENSION 
History:  
The medical history from a patient with portal hypertension should 
be directed towards determining the cause of portal hypertension and, 
secondarily, the presence of the complications of portal hypertension. 
Determining the cause of portal hypertension involves the following: 
* History of jaundice 
* History of blood transfusions, IV drug use (hepatitis B and C) 
* Pruritus 
* Family history of hereditary liver disease (hemochromatosis, 
Wilson disease) 
* History of alcohol abuse. 
 
 
 
 Determining the presence of the complications of portal hypertension 
involves the following: 
-   Hematemesis or melena (gastroesophageal variceal bleeding or 
bleeding from portal gastropathy) 
-   Mental status changes such as lethargy, increased irritability, and 
altered sleep patterns (presence of portosystemic encephalopathy) 
-   Increasing abdominal girth (ascites formation) 
-   Abdominal pain and fever (spontaneous bacterial peritonitis [SBP], 
which also presents without symptoms) 
-  Haematochezia (bleeding from portal colopathy) 
Physical :  
Signs of Porto systemic collateral formation include the following: 
-   Dilated veins in the anterior abdominal wall (umbilical epigastric 
vein shunts) 
-   Venous pattern on the flanks (portal-parietal peritoneal shunting) 
-   Caput medusa (tortuous collaterals around the umbilicus) 
-   Rectal haemorrhoids 
-   Ascites - Shifting dullness and fluid wave (if significant amount of 
ascitic fluid is present 
-   Para umbilical hernia 
 
 Signs of liver disease include the following: 
-  Ascites 
-  Jaundice 
- Spider angiomas 
-  Gynecomastia 
-  Dupuytren contracture 
-  Muscle wasting 
 - Palmar erythema 
 - Asterixis 
 -  Testicular atrophy 
 -  Splenomegaly 
Signs of hyperdynamic circulatory state include the following: 
- Bounding pulses 
- Warm, well-perfused extremities 
- Arterial hypotension. 
INVESTIGATIONS 
Endoscopy
(7,8)
 
The size of varix must be graded  
• Grade 1 (Fl): the varices can be depressed by the endoscope 
• Grade 2 (F2): the varices cannot be depressed by the endoscope 
 • Grade 3 (F3) the varices are confluent around the circumference of 
the oesophagus. 
CONN'S GRADING 
• Grade I - small varices detectable on valsalva only 
• Grade II -1-3 mm varix- in both phases of respiration 
• Grade III - 3-6 mm varices, not occluding the lumen 
• Grade IV - >6mm varices, occluding the lumen 
Larger the varix, the chances of bleeding is more. Varices usually 
appear white and opaque. Dilated sub epithelial veins may appear as 
raised cherry red spots and red whale markings. The haemocystic spot 
is approximately 4mm in diameter. It represents blood coming from 
deeper extrinsic veins of oesophagus straight out towards the lumen 
through a communicating vein into the more superficial submucosal 
veins. Red colour sign is usually associated with larger varices. All these 
colour changes and particularly the red colour sign predict variceal 
bleeding. Portal hypertensive gastropathy is seen largely in the fundus. 
It is seen as a mosaic like pattern. Variceal (azygos) blood flow can be 
assessed during diagnostic endoscopy by a Doppler US probe passed 
down the biopsy channel of the standard gastroscopy. 
 
 
 Imaging the portal venous system 
Ultrasound: 
A large portal vein suggests portal hypertension. If collaterals are 
seen, this confirms portal hypertension. 
Doppler ultrasound
(13)
 
Hepatofugal Flow in the Portal Venous System: Pathophysiology, 
Imaging Findings, and Diagnostic Pitfalls 
Doppler ultrasound helps in assessing the direction of flow in the 
main portal vein and its main tributaries and branches, and also in 
assessing the characteristic flow patterns described in relation to the 
cardiac cycle. 
Normal portal venous flow is Hetatopetal (towards the liver).when 
the portal vascular resistance begins to increase, the flow may become 
reversed (Hepatofugal or away from the liver) or a mixed pattern 
dependent on the phases of the cardiac cycle. 
At Doppler US, hepatofugal flow appears as flow directed away 
from the liver in the portal vein, its intrahepatic branches, or its extra 
hepatic tributaries. If hepatofugal flow is present in the main portal vein 
or an intrahepatic branch, flow is noted in the direction opposite to flow 
in the adjacent hepatic artery. Depending on the anatomic orientation of 
the involved vessel relative to the transducer, a Doppler shift above or 
 below the baseline can be produced by hepatofugal flow. A narrow portal 
vein and a prominent hepatic artery are common associated gray-scale US 
findings when flow is hepatofugal in the main portal vein. To-and-fro 
(bidirectional) blood flow, in which flow alternates between hepatopetal 
and hepatofugal during each cardiac cycle, has been observed to precede 
the development of frank hepatofugal flow in some patients with cirrhosis 
and is the correlate of stagnant flow in the portal vein noted at 
arteriography. 
  With few exceptions, hepatofugal flow in the main portal vein or 
an extrahepatic portal vein tributary is a specific sign of portal 
hypertension. One exception is hepatofugal flow in a liver transplant 
recipient with a large, persistent portosystemic collateral vessel that can 
divert a substantial amount of splanchnic venous blood; this diversion can 
interfere with graft function and portal vein patency but does not indicate 
recurrent portal hypertension. Another rare exception is hepatofugal flow 
caused by a congenital portosystemic collateral vessel. Hepatofugal flow 
in one or more solely intrahepatic portal veins can occur in patients with a 
focal arterio portal shunt and is therefore not specific for portal 
hypertension. 
 
 
  
 
 
 
Opposite flow directions in the portal vein and adjacent hepatic 
artery in a patient with cirrhosis and portal hypertension. Transverse 
colour Doppler US image shows intrahepatic portal vein branches 
(white*) containing blue signal adjacent to hepatic artery branches 
(black*) containing red signal. Because blood flow is normally 
hepatopetal in both the portal vein and the hepatic artery, opposite colour 
signals in adjacent branches of these two circulations indicate hepatofugal 
portal vein flow. 
 
 
 
  
Spectral Doppler waveform of the Hepatic Veins 
 
The normal hepatic vein waveform, despite commonly being 
described as triphasic, has four components: a retrograde A wave, an 
antegrade S wave, a transitional V wave (which may be ante grade, 
retrograde, or neutral), and an antegrade D wave. 
The A wave corresponds to atrial contraction. With the tricuspid 
valve open, blood is propelled in two directions: ante grade toward the 
right ventricle and retrograde toward the IVC and into the hepatic veins. 
At the end of atrial systole, peak retrograde velocity away from the heart 
 is achieved. As ventricular systole commences, the tricuspid valve closes 
and the retrograde velocity toward the hepatic veins begins to decrease 
and approach the baseline. 
During ventricular systole, not only do the ventricular walls 
contract to propel blood into the right ventricular outflow tract, but there 
is also movement of the tricuspid valve annulus toward the cardiac apex. 
These actions create a relative negative pressure in the atrium, causing 
antegrade blood flow out of the liver and into the heart during the S wave. 
In the normal heart, the largest amount of antegrade blood flow is during 
this phase. 
The V wave corresponds to atrial overfilling. As the ventricular 
contraction becomes less intense and the closed tricuspid valve begins to 
return to its original position, the atrium fills and blood flow velocity 
toward the heart decreases. The peak of the V wave may be below, at, or 
above the baseline, depending on whether there is ante grade flow 
throughout, transient equilibrium with no flow, or transient retrograde 
flow, respectively. The term triphasic does not include the V wave, 
perhaps because this wave represents only a transitional phase. 
The D wave begins as the tricuspid valve opens. During cardiac 
diastole, the right atrium and ventricle fill passively, with ante grade flow 
of blood from the liver into the heart. In the normal patient, the velocity 
 of this passive flow is almost always lower in magnitude than the velocity 
during the S wave. 
A normal variant, termed the C wave, can cause a small retrograde 
spike following the A wave. As atrial systole ends and ventricular systole 
commences, the tricuspid valve closes. The tricuspid annulus begins to 
move toward the cardiac apex and the retrograde velocity of flow toward 
the liver begins to decrease. However, before the pulmonic valve opens, 
the pressure in the ventricle increases with continuing contraction of the 
ventricle, causing a transient bulging of the tricuspid valve into the right 
atrium. This bulging creates a momentary retrograde pulse toward the 
liver, causing the C wave. When the pulmonic valve opens and blood is 
ejected from the right ventricle into the pulmonary outflow tract, the 
bulge in the tricuspid valve is relieved. Flow into the heart then resumes 
as usual during the S wave. 
 
 When a patient develops cirrhosis and portal hypertension as its 
sequel, the hepatic veins progressively fail to reflect the pressure changes 
in the right atrium. This will lead to the loss of normal triphasic pattern of 
the hepatic venous flow; which will become biphasic and later 
monophasic flow. 
Duplex Doppler has-been used to measure portal blood flow. In 
cirrhosis, the portal vein velocity tends to fall and when less than 6cm/s 
portal hypertension is likely. 
C.T scan 
After contrast, portal vein patency can be established and 
esophageal varices may be shown as intraluminal protrusions enhancing 
after contrast. Gastric varices show as rounded structures, 
indistinguishable from the gastric wall. 
In cirrhosis, the venogram varies widely. It may be completely 
normal or may show filling of large numbers of collateral vessels with 
gross distortion of the intra-hepatic pattern ('tree in winter appearance). 
BLEEDING OESOPHAGEAL VARICES
(15,16,17,18,19,20)
 
Variceal bleeding is the most serious complication of portal 
hypertension. Gastroesophageal varices are present in 50−60% of 
cirrhotic patients and about 30% of these patients will experience an 
episode of variceal hemorrhage within one year of the diagnosis of 
 varices. After the initial bleed, the risk of variceal rebleeding reported in 
the literature ranges from 50- 80%. About one half of all rebleeds occur 
within the first six weeks . Risk of rebleeding is very high in survivors of 
an episode of haemorrhage; in approximately 70% of patients, this will 
occur in the first few days following the first hemorrhage. 
Predicting rupture
(21)
 
The presence of the following factors are more often associated with 
bleeding risk. 
1. Size of the varices - large varices were found to have bled 
significantly more often than small varices. 
2. Colour of varices – The bleeding rate of blue coloured varices was 
63%, which was significantly more than white varices. 
3. Red colour sign - The three endoscopic signs studied, 
cherry red spots,  
red wale markings and  
haematocystic spots  
 are more often present in bleeders than in non-bleeders. 
 4. Location of varices - Rate of bleeding for varices extending up to 
locus superior was more than the varices belonging to locus medialis and 
locus inferior. 
 5. Form of varices - enlarged and tortuous varices bled more often than 
the straight varices. 
6. Intravariceal pressure - patients with higher pressures bled more often. 
Prevention of bleeding 
Liver function must be improved, for instance, by abstaining from 
alcohol. Aspirin and NSAIDs should be avoided. Propranolol is a non-
selective β-blocker, which reduces portal pressure by splanchnic 
vasoconstriction and, to a lesser extent, by reducing cardiac output. The 
drug is given in a dose, which reduces the resting pulse rate by 25% 12h 
after intake. 
The portal pressure must be maintained at 12mm Hg or lower. 
Propranolol is recommended for those with large varices and with red 
endoscopic danger signs. Patients with an HVPG greater than 12mmHg 
should be treated whatever the size of the varices. Nadolol gives 
equivalent results. Isosorbide-5 mononitrate is equally effective in 
prophylaxis of the first bleed, but the probability of death is significantly 
greater, particularly in those more than 50 years old. The addition of 
nitrate to β-blocker should be reserved for those failing therapy with the 
β-blocker alone. Variceal sclerotherapy or ligation is not so satisfactory 
or cost effective as vaso-active active drugs. 
 
 Prognosis 
Between 30 and 50% will die within 6 weeks of the first bleed. The 
prognosis is determined by the severity of the hepato-cellular disease. 
The ominous triad of jaundice, ascites and encephalopathy is associated 
with 80% mortality. The 1-year survival in good-risk (Child grade A and 
B) patients is about 85% and in bad - risk (Child grade C) patients about 
30%. Alcoholics have a worse prognosis, as hepatocellular disease is 
greater.  Abstinence from alcohol considerably improves the prognosis. A 
low portal blood velocity by Doppler predicts shorter survival. 
PLATELET COUNT/SPLENIC DIAMETER RATIO 
Gianni et al(2003)
(3)
 proposed platelet count/ splenic diameter ratio 
as a non-invasive marker for predicting esophageal varices in patients 
with liver cirrhosis. Parameters directly or indirectly linked to portal 
hypertension, such as splenomegaly and decreased platelet count, were 
predictors of the presence of esophageal varices. However, in patients 
with chronic liver disease the presence of decreased platelet count may 
depend on several factors other than portal hypertension, such as 
shortened platelet mean lifetime, decreased thrombopoietin production, or 
myelotoxic effects of alcohol or hepatitis viruses. On the other hand, the 
presence of splenomegaly in cirrhotic patients is likely the result of 
vascular disturbances that are mainly related to portal hypertension. With 
 this in mind, the study used the platelet count/spleen diameter ratio as a 
parameter linking thrombocytopenia to spleen size in order to introduce a 
variable that takes into consideration the decrease in platelet count which 
most likely depends on hypersplenism caused by portal hypertension. 
In the study Maximum spleen bipolar diameter was estimated by 
means of ultrasound scan and was expressed in millimetres (mm). Platelet 
count/spleen diameter ratio of all patients was calculated. They found that 
Spleen diameter was higher while platelet count/spleen diameter ratio 
was lower in patients with esophageal varices. Receiver operating 
characteristic curve (ROC curves) were used to assess the platelet 
count/spleen diameter ratio cut off with the best sensitivity and specificity 
for a diagnosis of esophageal varices (cut off=909, sensitivity=100% 
(95% CI 100–100); specificity=93% (95% CI 82–98)) . The prevalence 
adjusted positive and negative predictive values for a platelet 
count/spleen diameter ratio 909 were 96% and 100%, respectively. 
Moreover, accuracy of this platelet count/spleen diameter ratio cut off as 
evaluated by the c index was 0.981 (95% CI 0.943– 0.996). Both spleen 
diameter and platelet count cut offs with the best sensitivity and 
specificity for a diagnosis of esophageal varices that were identified by 
means of ROC curves had prevalence adjusted positive and negative 
predictive values and accuracies that were lower than those of the platelet 
 count/spleen diameter ratio. Gianni et al (2003)
 (3)
 report that the use of 
this ratio is of interest and is not redundant, and this hypothesis is 
supported by a number of both clinical and statistical reasons. Firstly, 
from a clinical point of view, platelet count may decrease for several 
reasons in patients with chronic liver disease. 
Thus the use of platelet count alone as a non-invasive predictor of 
esophageal varices can be misleading and cannot be solely attributed to 
portal hypertension. Indeed, the use of the platelet count/spleen diameter 
ratio bypasses this possible drawback since it "normalizes" platelet count 
to splenic sequestration, most likely representing the aliquot of 
thrombocytopenia caused by portal hypertension. Secondly, from a 
statistical point of view, the platelet count/spleen diameter ratio was the 
only parameter independently associated with the presence of esophageal 
varices that was selected by a multi variate analysis which also included 
the single parameters. 
The study showed that the use of the platelet count/spleen diameter 
ratio would have avoided performing unnecessary endoscopies in all 
patients with a cut off >909 without running the risk of not diagnosing 
esophageal varices. As far as cost benefit analysis is concerned, applying 
the "platelet count/spleen diameter ratio strategy" would lower the cost of 
oesophageal varices screening in patients with cirrhosis. 
 MATERIALS AND METHODS 
Type of Study :  Cross sectional study. 
Sample  : Gastroenterology, Department and Medicine  
    Out Patient Department and In patient wards of  
    Madurai Medical College, 
Duration of study :  May  2011 – November 2011 
INCLUSION CRITERIA 
All newly diagnosed cases of cirrhosis liver, based on physical 
examination, biochemical parameters, ultrasound abdomen and upper GI 
endoscopy. 
EXCLUSION CRITERIA 
-  Present or previous history of portal hypertensive bleeding 
-  Patients with hepatocellular carcinoma 
-  Portal vein thrombosis 
-  Previous or current treatment with β blockers, diuretics or other 
            vasoactive drugs.  
- Budd Chiari Syndrome 
- Patients with coexisting heart disease 
METHODOLOGY 
 Detailed history was taken from the patients and a complete 
physical examination of patients was carried out. In particular attention 
was paid to look for signs of liver cell failure like the spider, palmar 
 erythema, and parotid enlargement, palmar erythema,Duptyrene 
contractions. History regarding cause of admission was taken. history 
regarding upper GI bleeding (haematemesis, melena),fever,painful 
ascites, jaundice was taken. history regarding encephalopathy and 
possible precipitating factors were taken. Duration of diagnosis and 
duration of treatment was noted. History regarding alcohol consumption 
and History regarding Hepatitis B and Hepatitis C were taken. 
 A careful examination of abdomen for ascites, hepato 
spleenomegaly, CNS examination to detect Hepatic encephalopathy 
including testing for constructional apraxia.24 hour urine output was 
noted in all patients to exclude patients with oliguria. 
 The following investigations were carried out:  
1. Complete haemogram. 
2. Urinalysis including morning spot PCR 
3. LFT  
4.  Complete Hemogram 
         Hemoglobin (g/dL)     MCV (fL) 
        Count (cells/cmm)     MCHC (g/dL) 
Differential Count      PCV 
RBC (millions/cmm)     Clotting Time 
Platelets (lakhs/cmm)     Bleeding Time 
 5. Liver Function Tests 
Serum Bilirubin    Aspartate  
Amino Transferase  Serum Albumin   
Alanine Amino Transferase 
Prothrombin Time   Alkaline Phosphatase 
6. Child Pugh Score - Graded into Class A B or C 
7.  Ascitic Fluid Analysis 
 Colour     Protein 
 Cell Count     Differential count 
Sugar     SAAG 
8.  Ultrasound Abdomen with Doppler. 
Liver Surface Nodularity Portal Vein Size 
Architecture of the liver 
Hepatic venous wave forms 
Splenic vein size, Size of the liver, Spleen bipolar diameter 
Presence of ascites, Collateral circulation 
9. Upper Gastrointestinal Endoscopy 
   Presence of oesophageal and gastric varices and grading according to
  Conns grading for esophageal varices . 
Portal Hypertensive Gastropathy 
Erosions,   Red Signs  
 PROCEDURE 
Forty nine patients with cirrhosis liver, attending the medical and 
gastroenterology wards and outpatient departments of Madurai Medical 
College, Chennai, between the months of May 2011 to November 2011 
were selected, based on inclusion and exclusion criteria. 
All patients in the study underwent a full clinical evaluation 
.Clinical history and physical examination findings were recorded with 
particular attention to present or previous hematemesis, malena, bleeding 
per rectum, bleeding tendencies, alcoholism, blood transfusion, intake of 
hepatotoxic drugs, exposure to Sexually transmitted diseases, IV drug 
abuse, jaundice, anemia, edema, stigmata of chronic liver disease, dilated 
abdominal veins, ascites, splenomegaly and encephalopathy. 
All patients underwent biochemical tests, like liver function tests, 
complete blood counts, renal function tests, prothrombin time, 
ultrasonography of the abdomen to confirm the presence of cirrhosis and 
to record the spleen bipolar diameter, portal vein size, ascites and 
presence of collaterals and ascitic fluid analysis in patients with ascites. 
Upper GI endoscopy was done in all patients to confirm the presence of 
varices and also to grade them. Data were collected in a predetermined 
proforma and results were analysed using Epi Info software. 
 Continuous variables were analyzed using t-test and categorical 
variables by Chi square test. Pearson Correlation was used to find 
correlation between two variables. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  RESULTS 
 
Table 1 
Variables under study. 
VARIABLE VALUE 
Age ( in years) 43.8 +  10 
Sex Male : 34(68%)    Female : 15(32%) 
Ascites Nil – 21(44%); Mild- 8(16%); Moderate- 14(28%); 
Severe- 6(12%) 
UGI bleed Yes – 24(48%); No – 25(51%) 
Varices Grade 0 - 4(8%); 1 – 11(22%); 2 – 18 (36%); 3 – 16 (34%) 
Child Score A – 7 (14%);  B – 30( 60%);  C – 12 (26%) 
Hepatic flow Mono – 34 (70%); Biphasic – 8(12%);  
Triphasic – 7(14%) 
 
The mean age   =  43.84 years 
Standard deviation  =  9.926 
Range    =  27 yrs to 60 yrs. 
Males constituting  = 68%. 
Male female ratio             =        2.125  : 1  
 
  
GRAPH 1 : COMPENSATED AND DECOMPENSATED CIRRHOSIS. 
 
 
 
 
GRAPH 2 : ASCITIS 
 
 
 
 
  
 
 
  
TABLE 2 : Child –Pugh score 
 
 Number of 
patients 
Percentage 
A 7 14 % 
B 30 60 % 
C 12 26 % 
 
Majority of the patients ( 60%) belonged to Child class B whereas 
14% and 26% of patients belonged to child class A and C respectively. 
The most common identifiable cause of cirrhosis was Alcoholism. 
Hepatitis B and C patients were excluded from the study. 
          The mean duration after diagnosis was 2.26 years for the sample.  
           Eleven (22%) out of the total 50 patients were having compensated 
cirrhosis while the rest 88% were decompensated. 
 
 
  
 
 
 
Table - 3 
Hepatic venous wave forms 
 Number Percent 
Monophasic  34 70% 
Biphasic  8 16% 
Triphasic 7 14% 
 
 
Eighty eight per cent of the patients in our study were having 
decompensated cirrhosis. 
Thirty four (68%) of the patients showed a monophasic pattern of 
hepatic venous flow as against Eight patients (16%) with Biphasic flow 
pattern and Seven patients (14%) with monophasic flow pattern. 
         On breaking up further, thirty (88.2%) of the thirty four patients 
with monophasic flow were decompensated, as against eight (100%) with 
Biphasic flow and none (0%) with the normal triphasic flow pattern.  
 
  
 
 
 
GRAPH – 3   HEPATIC FLOW AND DE COMPENSATION 
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Table 4 
HEPATIC FLOW AND CHILD SCORE /  
VARICES GRADE / BLEED 
 
 
HEPATIC 
FLOW 
 
CHILD SCORE 
 
VARICES GRADE 
 
UGI BLEED 
A B C SMALL 
(1) 
LARGE 
(2 &3) 
YES NO 
No. % No. % No. % No. % No. % No. % No. % 
Mono (34) 4 11.8 20 58.8 10 29.4 3 8.8 31 91.2 18 52.9 16 47.1 
Biphasic(8) - - 6 75 2 25 5 62.5 3 37.5 5 62.5 3 37.5 
Abnormal 
total(42) 
4 9.5 26 61.9 12 28.6 8 19 34 81 23 54.8 19 45.2 
Tri 
phasic(7) 
{Normal} 
3 42.9 4 57.5 - - 6 14% 1 86% 1 14% 6 86% 
‘p’ for 
A & C 
B& C 
 
0.0362 Significant 
0.2448 Not significant 
 
 
0.0004 
Significant 
 
0.055 
Not Significant 
 
 
 
 
 
  
GRAPH 4 : HEPATIC FLOW AND CHILD SCORE 
 
 
 
 
GRAPH 5 : HEPATIC FLOW AND VARICIAL GRADE 
 
 
 
 
 
 
  
 
 
GRAPH 6 : HEPATIC FLOW AND UGI BLEED 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Relationship between hepatic flow and Child Pugh score: 
Out of the forty two patients with abnormal flow (biphasic and 
monophasic), four (9.5%) belonged to Child A, twenty six (61.9%)  
belonged to child B and twelve (28.6%)  belonged to child C class of 
cirrhosis. The association of A and C class of cirrhosis to abnormal 
hepatic flow pattern was found to be significant, with a ‘p’ value of 
0.0362. 
Relationship between hepatic flow and varicial grade. 
Eighty one per cent patients with an abnormal flow pattern had 
either grade 2 or 3 varices and one patient with normal hepatic venous 
flow had large varix. The association was very much significant with a 
‘p’ value of 0.0004 
Relationship between hepatic flow and varicial grade 
The association between abnormal flow pattern and the presence of 
UG bleed was again significant with a ‘p’ value of 0.0077 
Sensitivity    :  97% 
Specificity  :  43 % 
Positive predictive value : 81% 
Negative predictive value : 86% 
 
  
Relationship between hepatic flow and UG bleed: 
No statistically significant association 
Fisher exact ‘p’ value = 0.055  
Sensitivity  :  96% 
Specificity  :  24% 
Positive predictive value : 55% 
Negative predictive value : 86% 
 
Table - 5  
Platelet count/ splenic diameter ratio. 
 Platelet count Splenic diameter 
(in mm) 
Range  70,000 – 1,80,000 105 - 220 
Mean  1,20,060 144.6 
Median 1,20,000 145 
SD 23,295.84 19.79 
 
 
 
 
  
 
Table - 6 
Platelet count/spleen diameter ratio to grade of varices correlation 
Platelet 
count/spleen size 
Large varices + small varices - 
     < 909 39 4 
> 909 3 3 
 
Odds ratio 9.7500 
95 % CI 1.4545  to  65.3586 
z statistic 2.346 
P = 0.0190 
Sensitivity  : 93% 
Specificity  : 43% 
Positive predictive value : 90.7 % 
Negative predictive value : 50% 
 
 
 
  
 
GRAPH 7: PLATELET COUNT/SPLEEN DIAMETER RATIO TO 
GRADE OF VARICES CORRELATION 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
Table - 7 
 Hepatic waveforms Vs Platelet count/splenic diameter ratio  In 
predicting large varices  
 PC/SD ratio Hepatic venous 
doppler 
‘p’ value  0.0190 0.0001 
sensitivity 93% 97% 
specificity 43% 43% 
Positive predictive value 90.7% 81% 
Negative predictive value 50% 86% 
 
 
 
 
 
 
 
 
 
 DISCUSSION 
Cirrhosis liver is an important cause of morbidity and mortality 
across the world. Very often, cirrhotic patients are too debilitated to 
undergo various invasive investigations like OGD scopy that forms an 
integral part of the work up and follow up of these patients. 
Early reports
(21,22,23,24,25)
 about the usefulness of non invasive 
predictors of esophagial varices began to appear in medical literature 
around the commencement of the new millennium. 
Christophe Pilette et al
(23)
 in 1999 reported a diagnostic accuracy of 
72 % using 3 variables, Platelet count, Prothrombin time and spider 
naevi, if taken togather. They also reported that the best threshold for the 
diagnostic accuracy of platelet count was 160000 per dL providing a 
sensitivity of 80% and a specificity of 58%. Platelet count ≥260000 per 
dL has a negative predictive value ≥91%. 
Several markers
(33,35,36)
 have been studied, and among them platelet 
count is commonly reported to be a good predictor of oesophageal 
varices. The major drawback of platelet count is that it can depend on 
factors other than portal hypertension in cirrhotic patients. To avoid this 
bias, Giannini et al in 2003
(3)
 developed an index based on platelet count/ 
spleen diameter ratio and found far better results than previous studies. 
 In their study, 145 patents were enrolled. 103 patients were male 
and 42 were female, mean age 61 years with a range of 30–86 yrs. 
WW Baig et al in their study undertaken at Kasturba Medical 
college in Karnataka between 2004 and 2007 enrolled a total of 105 
patients, of whom One hundred twenty-six men and 24 women were 
included in the study. The mean age was 51 years (range 20 to 80 years). 
A study by Jijo et al
(27) 
at Stanley medical college, Chennai in 2009 
enrolled 229 patients of whom 141 were males and the rest were females. 
The median age was 42 yrs with a range of 17 to 73 yrs. 
A similar, but smaller study conducted at Thiruvananthapuram 
medical college by Thomas Joseph et al
(28)
 included 51 patients of whom 
44 were males and 7 were females. 
In our study, 49 patients were enrolled of whom 34 were males and 
15 were females. Mean age of patients studied here is 43.84 ±10 yrs.the 
male to female ratio was 2.125 : 1. 
Etiological evaluation could not done in our study due to 
economical constrains of  the  Govt. institution. The majority of alcohol 
patients is due to the selection bias. Joshi et al have reported   etiological 
figure in their study HBV (30%), alcohol (20%), HCV (14%). Masahiko 
koda et al showed HBV (33%),HCV(54.2%),alcohol (7%),primary biliary 
cirrhosis(4%). 
 Giannini in his original study in 2003, for the first time identified 
Platelet count/ Splenic diameter ratio as the most useful independent non 
invasive predictor of varices. They reported an odds ratio 0.527 and a ‘p’ 
value of <0.0001. Sixty one per cent of their patients with varices had a 
platelet count/spleen diameter ratio <909 and 100% of patients with a 
platelet count/spleen diameter ratio >909 were free from varices. In the 
study by WW Baig et al,
 (26)
 the sensitivity and specificity for the platelet 
count to spleen diameter ratio cut-off of 909 were 80% and 89%, 
respectively and the positive and negative predictive values were 95.4% 
and 95.1%, respectively. 
In our study, the sensitivity was 93% and specificity was 43% 
when a cut of ≤ 909 was used as proposed by Giannini. 
Doppler assessment of Hepatic vein and using the loss of the 
normal triphasic hepatic venous wave forms as a marker for the presence 
of varices was attempted by Thomas Joseph et al
(28)
 from 
Thiruvanathapuram medical college hospital. In the 51 patients analysed 
by the, 4 had a triphasic pattern, 26 had a biphasic pattern and 21 had 
monophasic wave forms. Among the 49 patients we analysed, flow was 
triphasic in 7, biphasic in 8 and monophasic in 34 patients. The sensitivity 
of the study in predicting large esophagial varices (grade 2 and 3) was 
97% and the specificity was 43 %. The positive predictive value was 81 
 % and the negative predictive value was 86%. The study group from 
Trivandrum reported a sensitivity of 95.2%, a specificity of only 10%, 
positive predictive value of only 43% and a negative predictive value of 
75%. 
The delineation of varices into small and large rather than the 
presence and absence of varices is important because, the current AASLD 
guidelines
(29)
 suggest that the varices be graded as just small(<5mm) and 
large (>5mm) only patients with large varices will need prophylactic 
treatment with beta agonists and those with small varices just needs to be 
followed up. Our study has revealed a sensitivity of 97% for the loss of 
normal hepatic venous triphasic waveform in predicting large esophagial 
varices. This will further push the acceptance of non invasive methods in 
predicting and following up esophagial varices. 
 
 
 
 
 
 
 
 
  
SUMMARY AND CONCLUSIONS 
 
1. Loss of normal hepatic venous triphasic wave form is a very 
sensitive non invasive marker for predicting the presence of large 
esophagial varices with reasonably high positive and negative 
predictive value. 
2. Platelet count/splenic diameter ratio, if taken with a cut off of ≤909, 
can predict the presence of large esophagial varices with reasonably 
good accuracy. 
3. Comparing hepatic venous flow pattern to platelet count splenic 
diameter ratio,the formor is more strongly associated with the 
presence of large varices and scores over the latter in terms of 
negative predictive value. 
4. Both are comparable in terms of sensitivity, specificity and positive 
predictive value. 
5. Hepatic venous flow pattern did not have a statistically significant 
correlation with the incidence of UGI bleed. 
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LIMITATIONS OF THE STUDY 
 
1. Small population studied. 
2. Etiology of cirrhosis not taken into account. 
3.  Hepatic venous Doppler and platelet count/ splenic diameter 
ratio in the normal population not assessed. 
4.  No patients had grade 4 varices. 
 
 
 
 
 
 
 
  
 
 
USG ABDOMEN  
 PROFORMA 
S. No:    IP No:     Address: 
Name:    Age:      Sex: 
Unit/Ward: 
 
PRESENTING COMPLAINTS 
 
CLINICAL FEATURES  PAST HISTORY 
Hemetemesis 
Malena 
Bleeding PR 
Bleeding tendencies 
Anaemia 
Jaundice 
Pedal Oedema 
Stigmata of CLD 
Dilated veins 
Hepatomegaly 
Splenomegaly 
Ascites 
Encephalopathy 
 
 
 
 
 
 
 
 
 
 
 
 
Alcoholism 
Hepatitis 
Drugs 
Cardiac disease 
T2DM/HTN 
 
COMPLETE HEMOGRAM  BIOCHEMISTRY  
Hb (g/dL) 
TC (cells/cmm) 
DC 
RBC(millions/cmm) 
Platelet(Lakhs/cmm) 
MCV(fL) 
MCHC(g/dL) 
PCV 
PT/INR 
Peripheral smear 
Platelet count 
 
 
 
 
 
 
 
 
 
 
Blood urea 
Creatinine 
Serum Bilirubin 
        Total 
         Direct 
         Indirect 
Serum Protein 
        Albumin 
        Globulin 
AST 
ALT 
ALP 
 
 
 
 
 
 
 
 
 
 
 
 
  Cirrhosis 
Spleen bipolar 
Diameter (mm) 
Portal Vein size (cm) 
Splenic Vein (cm) 
Ascites 
Collaterals 
 
 
 
 
 
 
 
 
 
OGD scopy : 
 
Remarks 
 
 
 
 
 
USG ABDOMEN 
Liver architecture: 
Spleen : 
Portal vein: 
Hepatic venous doppler : 
CHILD PUGH SCORE 
 ABBREVIATIONS 
 
EV   –  Esophagial Varices 
OGD   –  Oesophago Gastro Duodenoscopy 
LEV   –  Large Esophagial Varices 
SAAG –  Serum Ascitis Albumin Gradient 
HBV   –  Hepatitis B 
HCV   –  Hepatitis C 
CT   –  Computerised Tomography 
EEG   –  Electro Encephalogram 
γ-GT   –  Gamma Glutamyl Transferase. 
INR   –  International Normalised Ratio 
HVPG  –  Hepatic Venous Pressure Gradient 
IVC   –  Inferior Vena Cava 
NSAID  –  Non Steroidal Anti Inflammatory Drugs 
ROC   –  Receiver operating characteristic curve 
LFT  –  Liver Function Tests 
SD   –  Standard Deviation. 
ALP   –  Alkaline Phosphatase 
ALT   –  Alanine Amino Transferase 
AST   –  Aspartate Amino Transferase. 
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1 Amsa 60 M severe nil 1 Mono 2 714.29 nil 0 0 nil nil 24 0.6 100000 C 140 
2 Bhoopathi 40 M moderate yes MHE Biphasic 0 827.59 nil 5 0 nil nil 42 0.5 96000 B 116 
3 Sripushpam 36 F nil yes 0 biphasic 2 1125.00 nil 2 nil nil nil 26 0.8 180000 B 160 
4 selvaraj 38 M moderate yes 2 mono 2 750.00 nil 3 13 nil nil 16 1.3 120000 C 160 
5 pandi 48 M mild nil 0 mono 3 766.67 nil 8 23 nil nil 28 1.5 115000 B 150 
6 petchiammal 60 F nil nil 0 mono 2 642.86 nil 4 0 nil nil 26 1.8 90000 A 140 
7 eluvi 58 F nil nil 0 mono 1 733.33 nil 4 0 nil nil 20 1.3 110000 B 150 
8 raja 40 M moderate yes MHE Mono 0 833.33 nil 2 22 nil nil 21 1.2 150000 C 180 
9 rajeswari 36 F nil nil 0 triphasic 2 1031.25 nil 7 nil nil nil 16 0.9 165000 B 160 
10 lakkusami 56 M mild yes 0 biphasic 1 833.33 nil 0 5 nil nil 24 1.5 125000 B 150 
11 kanimuthu 35 M mild yes 0 Mono 1 857.14 nil 0 8 nil nil 27 1.4 120000 C 140 
12 mariappan 53 M nil nil 0 Mono 3 866.67 nil 4 9 nil nil 29 1.8 130000 B 150 
13 muthupillai 60 M moderate yes MHE Mono 3 727.27 nil 2 26 nil nil 31 1.2 80000 B 110 
14 raghupathi 35 M mild nil 0 Mono 3 823.53 nil 4 4 nil nil 26 1.2 140000 B 170 
15 kannadasan 42 M moderate nil MHE Mono 1 800.00 nil 3 16 nil nil 30 1.6 120000 B 150 
16 glory 40 F mild yes 0 triphasic 2 915.49 nil 4 0 nil nil 28 1.8 130000 B 142 
17 balamurugan 40 M mild nil 0 Mono 1 775.86 nil 4 18 nil nil 21 1.8 90000 A 116 
18 chandrakumar 36 M mild nil 0 triphasic 1 923.08 nil 0 11 nil nil 29 1.9 120000 B 130 
 19 palanisamy 50 M nil yes 0 Mono 2 866.67 nil 4 18 nil nil 22 1.2 130000 B 150 
20 subbalakshmy 52 F nil nil 0 Mono 0 847.46 nil 3 0 nil nil 26 1.6 100000 A 118 
21 pitchai 58 M severe yes MHE Biphasic 2 1153.85 nil 0 23 nil nil 24 1.9 150000 C 130 
22 latha 36 F nil nil 0 triphasic 1 875.00 nil 0 0 nil nil 23 1.3 140000 A 160 
23 subramani 54 M nil nil 0 Mono 0 1000.00 nil 3 26 nil nil 26 1.2 160000 B 160 
24 MUNIYANDI 35 m nil nil MHE mono 2 718.75 nil 1 8 nil nil 22 1.4 115000 B 160 
25 ibrahim 46 M moderate nil 0 Mono 3 846.15 nil 2 9 nil nil 28 1.4 110000 A 130 
26 nagaraj 45 M nil nil 2 Mono 3 810.81 nil 3 18 nil nil 30 1.8 120000 C 148 
27 murugan 37 M moderate nil MHE Mono 1 1080.00 nil 0 2 nil nil 19 1.6 135000 B 125 
28 selvaraj 40 M moderate yes 1 Mono 3 857.14 nil 4 13 nil nil 18 1.7 120000 C 140 
29 basha 54 M severe yes 1 Biphasic 3 538.46 nil 6 20 nil nil 26 1.2 70000 C 130 
30 sulthani 55 F nil yes 3 Mono 3 505.88 nil 0 0 nil nil 24 1 86000 B 170 
31 chinnakannan 38 M moderate yes 0 Mono 3 700.00 nil 2 9 nil nil 22 1.4 112000 B 160 
32 peyammal 30 F moderate yes 0 Mono 2 862.07 nil 1 0 nil nil 28 1.6 125000 C 145 
33 pandiyammal 38 F nil yes 0 Mono 2 866.67 nil 3 0 nil nil 24 1.8 130000 B 150 
34 parameswaran 27 M nil nil 0 triphasic 3 568.18 nil 0 0 nil nil 22 1.4 125000 A 220 
35 ganesan 28 M nil nil 0 Biphasic 2 1000.00 nil 0 6 nil nil 21 1.6 140000 B 140 
36 uma 29 F moderate yes 2 Mono 2 681.48 nil 2 0 nil nil 20 1.8 92000 C 135 
37 nithya 35 F nil yes 0 Biphasic 2 896.55 nil 3 0 nil nil 26 1.9 130000 B 145 
38 petchiammal 55 F nil yes 0 Mono 2 884.62 nil 4 0 nil nil 26 1.4 115000 A 130 
39 murugesh 45 M nil nil 0 Biphasic 3 782.61 nil 4 11 nil nil 22 1.6 90000 B 115 
40 kannan 39 M severe yes 2 Mono 2 857.14 nil 6 9 nil nil 27 1.6 120000 C 140 
41 muthupandi 49 M nil yes 0 Mono 3 900.00 nil 2 16 nil nil 24 1.6 135000 B 150 
42 muthammal 58 F moderate yes MHE Mono 1 967.74 nil 0 0 nil nil 28 1.8 150000 B 155 
43 subramanian 40 M severe yes 3 Mono 2 761.90 nil 3 16 nil nil 22 1.4 80000 C 105 
 44 lalitha 35 F nil nil 0 triphasic 2 903.23 nil 2 0 nil nil 22 1.4 140000 B 155 
45 lakshman 57 M nil nil 0 triphasic 1 896.55 nil 5 18 nil nil 29 1.9 130000 B 145 
46 muthuraj 37 M severe yes 3 Mono 1 892.86 nil 2 6 nil nil 26 1.2 125000 C 140 
47 eswaran 59 M mild nil 0 Mono 3 774.19 nil 2 26 nil nil 27 1.2 120000 B 155 
48 sathyamoorthy 54 M moderate nil MHE Mono 3 700.00 nil 3 23 nil nil 22 1.6 98000 B 140 
49 selvapandi 35 M moderate nil MHE Mono 3 906.25 nil 0 10 nil nil 21 1.8 145000 B 160 
 
 
 
 
 
 
 
 
 
